Bempedoic acid: A nonstatin drug for the management of hypercholesterolemia.
作者信息
Govindaraju Asvitha, Sabarathinam Sarvesh
机构信息
Department of Pharmacy Practice SRM College of Pharmacy, SRM IST Kancheepuram India.
出版信息
Health Sci Rep. 2021 Nov 9;4(4):e431. doi: 10.1002/hsr2.431. eCollection 2021 Dec.
Abstract
摘要
相似文献
1
Bempedoic acid: A nonstatin drug for the management of hypercholesterolemia.
Health Sci Rep. 2021 Nov 9;4(4):e431. doi: 10.1002/hsr2.431. eCollection 2021 Dec.
2
Association of Bempedoic Acid Administration With Atherogenic Lipid Levels in Phase 3 Randomized Clinical Trials of Patients With Hypercholesterolemia.
JAMA Cardiol. 2020 Oct 1;5(10):1124-1135. doi: 10.1001/jamacardio.2020.2314.
3
Role of Bempedoic Acid in Dyslipidemia Management.
J Cardiovasc Pharmacol. 2020 Oct;76(4):376-388. doi: 10.1097/FJC.0000000000000887.
4
Bempedoic Acid: A First-in-Class Agent for Lowering Cholesterol Levels.
Sr Care Pharm. 2021 Jul 1;36(7):331-336. doi: 10.4140/TCP.n.2021.331.
5
Bempedoic Acid and Ezetimibe for the Treatment of Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Phase II/III trials.
Clin Drug Investig. 2021 Jan;41(1):19-28. doi: 10.1007/s40261-020-00989-1. Epub 2020 Dec 23.
6
Bempedoic acid for the treatment of hypercholesterolemia.
Expert Rev Cardiovasc Ther. 2020 Jul;18(7):373-380. doi: 10.1080/14779072.2020.1782744. Epub 2020 Jun 22.
7
Bempedoic acid: Review of a novel therapy in lipid management.
Am J Health Syst Pharm. 2021 Jan 5;78(2):95-104. doi: 10.1093/ajhp/zxaa352.
8
Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin/kexin type 9 inhibitor therapy: A randomized, controlled trial.
J Clin Lipidol. 2021 Jul-Aug;15(4):593-601. doi: 10.1016/j.jacl.2021.05.002. Epub 2021 May 28.
9
Efficacy and safety of bempedoic acid in patients not receiving statins in phase 3 clinical trials.
J Clin Lipidol. 2022 May-Jun;16(3):286-297. doi: 10.1016/j.jacl.2022.03.001. Epub 2022 Mar 13.
10
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Eur J Prev Cardiol. 2020 Apr;27(6):593-603. doi: 10.1177/2047487319864671. Epub 2019 Jul 29.
引用本文的文献
1
Therapeutic landscape of metabolic dysfunction-associated steatohepatitis (MASH).
Nat Rev Drug Discov. 2025 Mar;24(3):171-189. doi: 10.1038/s41573-024-01084-2. Epub 2024 Nov 28.
2
Established and Emerging Nucleic Acid Therapies for Familial Hypercholesterolemia.
Circulation. 2024 Aug 27;150(9):724-735. doi: 10.1161/CIRCULATIONAHA.123.067957. Epub 2024 Aug 26.
3
The Pleiotropic Effects of Lipid-Modifying Interventions: Exploring Traditional and Emerging Hypolipidemic Therapies.
Metabolites. 2024 Jul 17;14(7):388. doi: 10.3390/metabo14070388.
4
Isolation of 6-gingerol and semi-synthesis of 1,4-benzodiazepines derivatives: An in-situ pharmacokinetics properties, molecular docking and molecular dynamics simulation assessments.
Saudi J Biol Sci. 2024 Aug;31(8):104048. doi: 10.1016/j.sjbs.2024.104048. Epub 2024 Jun 10.
5
Efficacy and outcomes of bempedoic acid versus placebo in patients with hypercholesterolemia: an updated systematic review and meta-analysis of randomized controlled trials.
Cardiovasc Endocrinol Metab. 2024 Jun 20;13(3):e0302. doi: 10.1097/XCE.0000000000000302. eCollection 2024 Sep.
6
Regulation of cholesterol homeostasis in health and diseases: from mechanisms to targeted therapeutics.
Signal Transduct Target Ther. 2022 Aug 2;7(1):265. doi: 10.1038/s41392-022-01125-5.
本文引用的文献
1
Efficacy and safety of bempedoic acid in patients with hypercholesterolemia: A systematic review and meta-analysis of randomized controlled trials.
Eur J Prev Cardiol. 2021 Jul 23;28(8):825-833. doi: 10.1177/2047487320930585. Epub 2020 Jun 17.
2
Evaluating pharmacokinetics of bempedoic acid in the treatment of hypercholesterolemia.
Expert Opin Drug Metab Toxicol. 2021 Sep;17(9):1031-1038. doi: 10.1080/17425255.2021.1951222. Epub 2021 Jul 15.
3
Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: A systematic review and meta-analysis.
PLoS Med. 2020 Jul 16;17(7):e1003121. doi: 10.1371/journal.pmed.1003121. eCollection 2020 Jul.
4
Bempedoic acid, an inhibitor of ATP citrate lyase for the treatment of hypercholesterolemia: early indications and potential.
Expert Opin Investig Drugs. 2020 Aug;29(8):763-770. doi: 10.1080/13543784.2020.1778668. Epub 2020 Jun 21.
5
Effect of Bempedoic Acid on Serum Uric Acid and Related Outcomes: A Systematic Review and Meta-analysis of the available Phase 2 and Phase 3 Clinical Studies.
Drug Saf. 2020 Aug;43(8):727-736. doi: 10.1007/s40264-020-00931-6.
6
Time trends analysis of statin prescription prevalence, therapy initiation, dose intensity, and utilization from the hospital information system of Jinshan Hospital, Shanghai (2012-2018).
BMC Cardiovasc Disord. 2020 Apr 25;20(1):201. doi: 10.1186/s12872-020-01482-5.
7
Effect of Bempedoic Acid vs Placebo Added to Maximally Tolerated Statins on Low-Density Lipoprotein Cholesterol in Patients at High Risk for Cardiovascular Disease: The CLEAR Wisdom Randomized Clinical Trial.
JAMA. 2019 Nov 12;322(18):1780-1788. doi: 10.1001/jama.2019.16585.
8
ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review.
Prog Lipid Res. 2020 Jan;77:101006. doi: 10.1016/j.plipres.2019.101006. Epub 2019 Sep 6.
9
Bempedoic acid plus ezetimibe fixed-dose combination in patients with hypercholesterolemia and high CVD risk treated with maximally tolerated statin therapy.
Eur J Prev Cardiol. 2020 Apr;27(6):593-603. doi: 10.1177/2047487319864671. Epub 2019 Jul 29.
10
Safety and Efficacy of Bempedoic Acid to Reduce LDL Cholesterol.
N Engl J Med. 2019 Mar 14;380(11):1022-1032. doi: 10.1056/NEJMoa1803917.
Zotero 插件